Literature DB >> 11220751

Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase.

B A Minassian1, D M Andrade, L Ianzano, E J Young, E Chan, C A Ackerley, S W Scherer.   

Abstract

Lafora disease (LD) is the only progressive myoclonus epilepsy with polyglucosan bodies. Among conditions with polyglucosan bodies, LD is unique for the subcellular location of its polyglucosans in neuronal perikarya and dendrites and not in axons. Here we report that the protein encoded by the EPM2A gene, which is mutated in LD, localizes at the plasma membrane and the endoplasmic reticulum and that it is a functional protein tyrosine phosphatase. The significance of these findings in the epilepsy of LD and in the origin and characteristic subcellular location of Lafora bodies is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11220751

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22.

Authors:  E M Chan; D E Bulman; A D Paterson; J Turnbull; E Andermann; F Andermann; G A Rouleau; A V Delgado-Escueta; S W Scherer; B A Minassian
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

2.  Triacylglycerol mimetics regulate membrane interactions of glycogen branching enzyme: implications for therapy.

Authors:  Rafael Alvarez; Jesús Casas; David J López; Maitane Ibarguren; Ariadna Suari-Rivera; Silvia Terés; Francisca Guardiola-Serrano; Alexander Lossos; Xavier Busquets; Or Kakhlon; Pablo V Escribá
Journal:  J Lipid Res       Date:  2017-06-19       Impact factor: 5.922

3.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

Review 4.  Lafora disease, seizures and sugars.

Authors:  D M Andrade; J Turnbull; B A Minassian
Journal:  Acta Myol       Date:  2007-07

5.  Dimeric quaternary structure of human laforin.

Authors:  Rajeshwer S Sankhala; Adem C Koksal; Lan Ho; Felix Nitschke; Berge A Minassian; Gino Cingolani
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

Review 6.  Lafora disease offers a unique window into neuronal glycogen metabolism.

Authors:  Matthew S Gentry; Joan J Guinovart; Berge A Minassian; Peter J Roach; Jose M Serratosa
Journal:  J Biol Chem       Date:  2018-02-26       Impact factor: 5.157

Review 7.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 8.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

9.  Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease.

Authors:  Madushi Raththagala; M Kathryn Brewer; Matthew W Parker; Amanda R Sherwood; Brian K Wong; Simon Hsu; Travis M Bridges; Bradley C Paasch; Lance M Hellman; Satrio Husodo; David A Meekins; Adam O Taylor; Benjamin D Turner; Kyle D Auger; Vikas V Dukhande; Srinivas Chakravarthy; Pascual Sanz; Virgil L Woods; Sheng Li; Craig W Vander Kooi; Matthew S Gentry
Journal:  Mol Cell       Date:  2014-12-24       Impact factor: 17.970

10.  Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms.

Authors:  Runhua Liu; Lizhong Wang; Chong Chen; Yan Liu; Penghui Zhou; Yin Wang; Xirui Wang; Julie Turnbull; Berge A Minassian; Yang Liu; Pan Zheng
Journal:  Mol Cell Biol       Date:  2008-09-29       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.